[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 1981

Des-Tyrosine-γ-Endorphin Administration in Chronic SchizophrenicsA Preliminary Report

Author Affiliations

From the Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland, Baltimore (Drs Tamminga and DeFraites); the Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Md (Dr Tamminga, Chase, and DeFraites); and the Department of Psychiatry, University of Chicago (Drs Tighe and Schaffer).

Arch Gen Psychiatry. 1981;38(2):167-168. doi:10.1001/archpsyc.1981.01780270053006
Abstract

• The β-lipotrophin fragment des-tyrosine-γ-endorphin (DTγE) has been reported to have antipsychotic properties. We administered the compound without other psychoactive drugs to a subpopulation of schizophrenic subjects. Male patients with chronic psychotic illness and previous long-term neuroleptic therapy were given DTγE at a similar dose and duration of treatment that have been reported to be effective. No improvement in psychotic symptoms occurred; plasma prolactin level, a parameter characteristically altered by neuroleptic treatment, did not change. The beneficial effects of DTγE in schizophrenia may be specific to a diagnostic category, may be dependent on past pharmacologic treatment, or may occur only in combination with other drugs.

×